Ginsenoside Rh1 Exerts Neuroprotective Effects by Activating the PI3K/Akt Pathway in Amyloid-β Induced SH-SY5Y Cells
Source abstract
Abstract
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the accumulation of β-amyloid plaques and hyperphosphorylated tau proteins in the brain. Cell signaling pathways such as PI3K/Akt are known to play an essential role in regulating cell survival, motility, transcription, metabolism, and progression of the cell cycle. Recent studies demonstrated that the disruption of these signaling pathways in neurodegenerative disorders leads to oxidative stress and cell death. Targeting these altered signaling pathways could be considered as the therapeutic approach for neurodegenerative disorders. Ginsenoside Rh1 is known to provide beneficial effects in various diseases such as cancer, diabetes, and inflammation. In this study, human neuroblastoma SH-SY5Y cells were treated with the β-amyloid oligomers alone or in combination with ginsenoside Rh1. We observed that ginsenoside Rh1 was able to attenuate β-amyloid induced oxidative stress and cell death by activating the PI3K/Akt signaling pathway. Based on these findings, we suggest that ginsenoside Rh1 might be an efficacious therapeutic agent for AD.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Ginseng Biological Effects and Applications · Tryptophan and brain disorders · Pharmacological Effects of Natural Compounds
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Food and Nutrition, College of BioNano Technology, Gachon University, Seongnam-si 13120, Gyeonggi-do, Korea
Institute for Aging and Clinical Nutrition Research, Gachon University, Seongnam-si 13120, Gyeonggi-do, Korea
Funding
This work was supported by the GRRC program of Gyeonggi province. [GRRC-Gachon2020(B03), Development of Healthcare Contents based on AI]
References (58)
Show source-provided references
1. Dementia: What pharmacists need to know10.1177/1715163517690745 ↗
2. Measuring cognition and function in the preclinical stage of Alzheimer’s disease10.1016/j.trci.2018.01.003 ↗
3. Impact of social relationships on Alzheimer’s memory impairment: Mechanistic studies10.1186/s12929-018-0404-x ↗
4. Update on Alzheimer’s Disease Therapy and Prevention Strategies10.1146/annurev-med-042915-103753 ↗
5. Normal and abnormal biology of the beta-amyloid precursor protein10.1146/annurev.ne.17.030194.002421 ↗
6. Prince, M., Comas-Herrera, A., Knapp, M., Guerchet, M., and Karagiannidou, M. (2016). World Alzheimer Report 2016: Improving Healthcare for People Living with Dementia: Coverage, Quality and Costs Now and in the Future, Alzheimer’s Disease International.
7. Neuronal cell death in Alzheimer’s disease and a neuroprotective factor, humanin10.2174/157015906776359577 ↗
8. Coenzyme Q10 protects against amyloid beta-induced neuronal cell death by inhibiting oxidative stress and activating the P13K pathway10.1016/j.neuro.2011.12.005 ↗
9. Coenzyme Q10 restores amyloid beta-inhibited proliferation of neural stem cells by activating the PI3K pathway10.1089/scd.2012.0604 ↗
10. The glamour and gloom of glycogen synthase kinase-310.1016/j.tibs.2003.12.004 ↗
11. Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases10.1016/j.pharmthera.2014.11.016 ↗
12. GSK-3: Tricks of the trade for a multi-tasking kinase10.1242/jcs.00384 ↗
13. GSK-3 is essential in the pathogenesis of Alzheimer’s disease10.3233/JAD-2006-9S335 ↗
14. Glycogen synthase kinase-3 is a negative regulator of extracellular signal-regulated kinase10.1038/sj.onc.1209004 ↗
15. Role of p38/MAPKs in Alzheimer’s disease: Implications for amyloid beta toxicity targeted therapy10.1515/revneuro-2018-0008 ↗
16. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration10.1016/j.neuron.2010.11.030 ↗
17. Hyperphosphorylation of tau induces local polyproline II helix10.1021/bi052662c ↗
18. Ginsenoside Rh1 Possesses Antiallergic and Anti-Inflammatory Activities10.1159/000076383 ↗
19. Hyun, S.H., Kim, S.W., Seo, H.W., Youn, S.H., Kyung, J.S., Lee, Y.Y., Gyo, I., Park, C.-K., and Han, C.-K. (2020). Physiological and pharmacological features of the non-saponin components in Korean red ginseng. J. Ginseng Res.10.1016/j.jgr.2020.01.005 ↗
20. Ameliorative effects of black ginseng on nonalcoholic fatty liver disease in free fatty acid-induced HepG2 cells and high-fat/high-fructose diet-fed mice10.1016/j.jgr.2019.09.004 ↗
21. Ginseng pharmacology: Multiple constituents and multiple actions10.1016/S0006-2952(99)00212-9 ↗
22. Improvement of Memory in Mice and Increase of Hippocampal Excitability in Rats by Ginsenoside Rg1′s Metabolites Ginsenoside Rh1 and Protopanaxatriol10.1254/jphs.08060FP ↗
23. Anti-amnestic and anti-aging effects of ginsenoside Rg1 and Rb1 and its mechanism of action10.1111/j.1745-7254.2005.00034.x ↗
24. Anticarcinogenic effect of Panax ginseng C.A. Meyer and identification of active compounds10.3346/jkms.2001.16.S.S6 ↗
25. Ginsenoside Rp1, a ginsenoside derivative, blocks lipopolysaccharide-induced interleukin-1beta production via suppression of the NF-kappaB pathway10.1055/s-0028-1112218 ↗
26. Antihyperglycemic effects of total ginsenosides from leaves and stem of Panax ginseng10.1111/j.1745-7254.2005.00156.x ↗
27. Chemical Studies on the Oriental Plant Drugs. XVI. The Stereochemistry of Protopanaxadiol, a Genuine Sapogenin of Ginseng10.1248/cpb.14.1150 ↗
28. Lee, S., Lee, M., Ko, Y., Choi, H., Jeong, J., Choi, K.-M., Cha, J.-D., Hwang, S.-M., Jung, H., and Park, J. (2013). Effects of Extracts of Unripe Black Raspberry and Red Ginseng on Cholesterol Synthesis. Korean J. Food Sci. Technol., 45.10.9721/KJFST.2013.45.5.628 ↗
29. Anti-inflammatory mechanism of ginsenoside Rh1 in lipopolysaccharide-stimulated microglia: Critical role of the protein kinase A pathway and hemeoxygenase-1 expression10.1111/j.1471-4159.2010.07075.x ↗
30. A ginsenoside-Rh1, a component of ginseng saponin, activates estrogen receptor in human breast carcinoma MCF-7 cells10.1016/S0960-0760(03)00067-0 ↗
31. Gut microbiota-mediated pharmacokinetics of ginseng saponins10.1016/j.jgr.2017.04.011 ↗
32. Study on Transformation of Ginsenosides in Different Methods10.1155/2017/8601027 ↗
33. Ginsenoside Rh1 inhibits colorectal cancer cell migration and invasion in vitro and tumor growth in vivo
34. Mathiyalagan, R., Wang, C., Kim, Y.J., Castro-Aceituno, V., Ahn, S., Subramaniyam, S., Simu, S.Y., Jiménez-Pérez, Z.E., Yang, D.C., and Jung, S.-K. (2019). Preparation of Polyethylene Glycol-Ginsenoside Rh1 and Rh2 Conjugates and Their Efficacy against Lung Cancer and Inflammation. Molecules, 24.10.3390/molecules24234367 ↗
35. Suppressive Effects of Ginsenoside Rh1 on HMGB1-Mediated Septic Responses10.1142/S0192415X1950006X ↗
36. Ginsenoside Rh1 Ameliorates High Fat Diet-Induced Obesity in Mice by Inhibiting Adipocyte Differentiation10.1248/bpb.b12-00558 ↗
37. Fucoxanthin, a Marine Carotenoid, Attenuates β-Amyloid Oligomer-Induced Neurotoxicity Possibly via Regulating the PI3K/Akt and the ERK Pathways in SH-SY5Y Cells10.1155/2017/6792543 ↗
38. Ginsenoside compound K ameliorates Alzheimer’s disease in HT22 cells by adjusting energy metabolism10.1007/s11033-019-04988-0 ↗
39. Neuroprotective Effects of Ginsenoside Rf on Amyloid-β-Induced Neurotoxicity in vitro and in vivo10.3233/JAD-180251 ↗
40. Metabolic profiling of the effects of ginsenoside Re in an Alzheimer’s disease mouse model10.1016/j.bbr.2017.09.027 ↗
41. Effect of Ginsenosides on Prevention of Alzheimer’s Disease10.1088/1757-899X/612/2/022004 ↗
42. Baicalin and ginsenoside Rb1 promote the proliferation and differentiation of neural stem cells in Alzheimer’s disease model rats10.1016/j.brainres.2017.10.003 ↗
43. Role of ROS and Nutritional Antioxidants in Human Diseases10.3389/fphys.2018.00477 ↗
44. Singh, A., Kukreti, R., Saso, L., and Kukreti, S. (2019). Oxidative Stress: A Key Modulator in Neurodegenerative Diseases. Molecules, 24.10.3390/molecules24081583 ↗
45. Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis10.1007/s00401-015-1386-3 ↗
46. Oxidative stress and the pathogenesis of Alzheimer’s disease10.1155/2013/316523 ↗
47. Mitochondrial abnormalities and oxidative imbalance in Alzheimer disease10.3233/JAD-2006-9207 ↗
48. Anti-inflammatory effects of ginsenoside Rg1 and its metabolites ginsenoside Rh1 and 20(S)-protopanaxatriol in mice with TNBS-induced colitis10.1016/j.ejphar.2015.06.011 ↗
49. Ginsenoside Rh1: A Systematic Review of Its Pharmacological Properties10.1055/s-0043-124087 ↗
50. Protopanaxatriol Ginsenoside Rh1 Upregulates Phase II Antioxidant Enzyme Gene Expression in Rat Primary Astrocytes: Involvement of MAP Kinases and Nrf2/ARE Signaling10.4062/biomolther.2015.129 ↗
51. Inhibitory Effect of Ginsenosides Rh1 and Rg2 on Oxidative Stress in LPS-Stimulated RAW 264.7 Cells10.4167/jbv.2018.48.4.156 ↗
52. Ginsenoside Rh1 suppresses inducible nitric oxide synthase gene expression in IFN-gamma-stimulated microglia via modulation of JAK/STAT and ERK signaling pathways10.1016/j.bbrc.2010.05.117 ↗
53. Long-term administration of ginsenoside Rh1 enhances learning and memory by promoting cell survival in the mouse hippocampus10.3892/ijmm.2013.1552 ↗
54. Matsuda, S., Nakagawa, Y., Tsuji, A., Kitagishi, Y., Nakanishi, A., and Murai, T. (2018). Implications of PI3K/AKT/PTEN Signaling on Superoxide Dismutases Expression and in the Pathogenesis of Alzheimer’s Disease. Diseases, 6.10.3390/diseases6020028 ↗
55. The amyloid β peptide Aβ (25–35) induces apoptosis independent of p5310.1016/S0014-5793(00)01323-5 ↗
56. Mitotic signaling by β-amyloid causes neuronal death10.1096/fasebj.13.15.2225 ↗
57. Ginsenoside Rg1 prevents SK-N-SH neuroblastoma cell apoptosis induced by supernatant from Aβ1–40-stimulated THP-1 monocytes10.1016/j.brainresbull.2012.05.002 ↗
58. Exploring the Effect of Ginsenoside Rh1 in a Sleep Deprivation-Induced Mouse Memory Impairment Model10.1002/ptr.5797 ↗